title: Developments in high-yield system expressed vaccines and immunotherapy.
abstract: Conventional vaccine production techniques are outdated, leaving the world defenseless to viruses and pathogens. Successful protection necessitates the innovation of strategies that can generate an induced defensive humoral and cellular response with: ease of mass production, nominal side-effects, and controlled design specificity, all while being cost effective. Fortunately, technology exists to facilitate such advances in this billion dollar industry and this review is focused on recent publications and patents which hold promise to revolutionize the fight against pathogenic illnesses.
authors.affiliation: Biomedical Engineering Program, College of Engineering, University of Arkansas, 203 Engineering Hall, Fayetteville, AR 72701, USA.
authors.forename: Marissa
authors.initials: M
authors.lastname: Geels
authors.forename: Kaiming
authors.initials: K
authors.lastname: Ye
mesh_terms: D001428:Bacterial Vaccines / Q000096:biosynthesis; D003362:Cost-Benefit Analysis; D004274:DNA, Recombinant / Q000235:genetics; D004345:Drug Industry; D005822:Genetic Vectors; D006801:Humans; D007167:Immunotherapy; D007252:Influenza Vaccines / Q000096:biosynthesis*; D008565:Membrane Proteins / Q000378:metabolism; D010330:Patents as Topic; D016865:Reassortant Viruses; D011994:Recombinant Proteins / Q000378:metabolism; D014612:Vaccines / Q000096:biosynthesis*; D019444:Vaccines, DNA / Q000096:biosynthesis; D014614:Vaccines, Synthetic
chemical_list: D001428:Bacterial Vaccines; D004274:DNA, Recombinant; D007252:Influenza Vaccines; D008565:Membrane Proteins; D011994:Recombinant Proteins; D014612:Vaccines; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic